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Abstract
As the course of schizophrenic disorders is often chronic, treatment guidelines recommend continuous maintenance treatment 
to prevent relapses, but antipsychotic drugs can cause many side effects. It, therefore, seems reasonable to try to reduce doses 
in stable phases of the illness or even try to stop medication. We conducted a 26 weeks, randomized, rater blind, feasibility 
study to examine individualized antipsychotic dose reduction versus continuous maintenance treatment (Register Number: 
NCT02307396). We included chronic, adult patients with schizophrenia or schizoaffective disorder, who were treated with 
any antipsychotic drug except clozapine, who had not been hospitalized in the last 3 years and who were in symptomatic 
remission at baseline. The primary outcome was relapse of positive symptoms. Symptom severity, social functioning and 
side effects were also examined as secondary outcomes. 20 patients were randomized. Relapse rates in the two groups were 
not significantly different. No patient had to be hospitalized. One patient in the control group dropped out. The mean reduc-
tion of antipsychotic dose in the individualized dose-reduction group was 42%, however only one patient discontinued drug 
completely. There were no significant differences in efficacy or safety outcomes. This randomized trial provides evidence, 
that reduction of antipsychotic medication in chronic stable schizophrenic patients may be feasible. The results need to be 
confirmed in a larger trial with a longer follow-up period.
Keywords Randomized clinical trial · Antipsychotic maintenance treatment · Dose reduction · Chronic schizophrenia · 
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Introduction
Schizophrenia is a debilitating disorder with a frequently 
chronic course. Relapses are a common problem in schizo-
phrenia which are not only a heavy burden for patients and 
their relatives [1], but which also cause high socio-econom-
ical costs [2]. Around 80% of patients with a first episode 
experience another acute episode within 5 years [3]. There-
fore, prevention of relapse is a central goal of guideline-
based treatment. Antipsychotic drugs reduce relapse rates 
effectively from 64 to 27% after a year of treatment, as 
shown in a large meta-analysis [4]. Relapse rates were simi-
lar after 3–6 years [4]. Furthermore, a large cohort study 
has shown that long-term antipsychotic treatment prevents 
rehospitalization and reduces mortality in first episode 
patients [5]. Therefore guidelines recommend drug treat-
ment as first option for acute and maintenance treatment of 
schizophrenia [6, 7]. Nevertheless, reducing antipsychotic 
doses in chronic schizophrenic patients is an important 
goal, because antipsychotics produce many side-effects. 
For example, metabolic side-effects can accumulate over 
time leading to an increased cardiovascular risk for patients 
with schizophrenia [8]. Furthermore, studies suggest that 
treatment with antipsychotics may reduce brain volume in 
a dose-related fashion [9]. It is therefore important to find 
out by how much patients can reduce antipsychotic doses 
or in how many patients antipsychotics can be completely 
withdrawn. There are three main withdrawal options. First, 
abrupt stopping of the antipsychotic as often done in typical 
relapse prevention studies, an approach, which has consist-
ently been shown to increase relapse risk in placebo-treated 
patients [4]. Second, restarting antipsychotic treatment 
after complete withdrawal, if prodromal syndromes occur. 
This so-called intermittent treatment is also associated with 
higher relapse rates compared to continuous treatment [10]. 
A third option, often used in clinical routine, is the gradual 
dose reduction tailored to the individual patient symptoms 
and needs. The rationale is that there is probably a lot of 
interindividual variability of the doses needed for relapse 
prevention. Cohort studies have shown that up to one third 
of the patients with schizophrenia can stop medication and 
that these patients had more periods of recovery [11]. In a 
cohort study with first episode patients 30% had remission 
of psychotic symptoms with no current use of antipsychotic 
medication at 10-year follow up [12]. 50% antipsychotic 
dose reduction did not increase positive symptoms and even 
improved cognitive function and negative symptoms in two 
randomized controlled trials [13, 14]. In contrast, a 14-year 
follow-up study in rural China found (partial) remission rates 
of 57% in the group taking antipsychotics compared to 30% 
in a group that did not [15]. Overall many patients want to 
reduce medication, in particular, if they suffer from severe 
side effects (e.g. weight gain, sedation) which reduce their 
quality of life. Therefore, they often reduce doses without 
professional support. This can lead to severe relapses and 
sometimes, violent acts or even death due to suicide. Thus, 
dose reduction seems reasonable and recommendations from 
the user-movement initiated a general debate on reduction 
of medication [16, 17], but it probably needs to be carefully 
adapted to the individual patient´s psychopathological state. 
Such an approach was first systematically evaluated by Wun-
derink and colleagues. They tried gradual symptom guided 
tapering of dosage in stable first episode patients. Relapse 
rates were 20% higher in discontinued patients, but mostly of 
mild severity [18]. To examine, if gradual symptom guided 
dose reduction is possible in remitted chronic schizophrenic 
patients, we conducted a pilot feasibility study.
Methods
Study design and participants
We conducted a single-blind, randomised, controlled prag-
matic feasibility trial between November 5, 2014 and 30 
July 2016, in the outpatient department of the psychiatry 
department of the Technical University, Munich, Germany. 
Eligible participants were between 18 and 65 years old meet-
ing ICD-10 criteria for schizophrenia or schizoaffective dis-
order. The participants had to be stable for at least 3 years, 
defined by no psychiatric hospitalization, and they had to 
be continuously treated with antipsychotic medication with 
no changes in the last four weeks. There was no restriction 
in terms of the initially used antipsychotics and their doses, 
except for the exclusion of clozapine. This antipsychotic 
is reserved for treatment-resistant patients and assumed to 
be associated with a high risk for rebound psychoses [19]. 
Moreover, patients had to be in symptomatic remission of 
positive symptoms as defined by the following criteria:
1. PANSS-items (positive items of the Andreasen criteria 
[20]) < 4: delusions (P1), conceptual disorganisation 
(P2), hallucinations (P3), mannerisms and posturing 
(G5) and unusual thought content (G9).
2. CGI < 4 [21].
Further exclusion criteria were substance dependence 
other than tobacco dependency, suicidality, and initiation 
or dose change of antidepressants or mood stabilizers during 
the last six weeks before enrolment.
Our trial protocol was approved by the ethics commit-
tee of the Technical University of Munich and the trial is 
registered at clincialtrial.gov with the registration number: 
NCT02307396. All patients gave written informed consent 
prior to study inclusion.
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Randomisation and masking
Participants were recruited from outpatient clinics of psy-
chiatric hospitals, ambulant psychiatrists or newsletters to 
patient self-help groups in the area of Munich, Germany. 
Eligible participants were then randomized either to the 
intervention (reducing of medication) or control group (no 
dose reduction) via a fax from the trial coordinator to A.H. 
who had the randomization list. The randomization list was 
generated by an independent psychologist using the RAND 
function of Microsoft Excel 2010. Only once the patient was 
recorded, allocation was made known to the treating psy-
chiatrist and the participant. The ratings were done by clini-
cians who were blind to the allocation (C.L., P.R. and S.B.).
Procedures
In the intervention group, antipsychotic dose was gradually 
reduced and stopped if possible, based on the participant’s 
psychopathological status. As a rule the initial antipsychotic 
dose should be reduced by 1/6 every other week for the first 
three months, but this was adapted for each patient individu-
ally according to her/his needs and psychopathological sta-
tus. So antipsychotic doses were reduced as far as possible 
for the first three months and then patients were followed-up 
with stable medication for three months. Medication in the 
control group was maintained. Participants were provided 
with two tablets of lorazepam 1 mg as rescue medication, 
which were renewed, if used. Trial duration was 26 weeks 
with study visits every two weeks. The antipsychotic doses 
were adjusted by M.H., who treated the patients during the 
reduction. To ensure adherence to the study protocol, M.H. 
did a pill count at all study visits and drug levels were meas-
ured at baseline, after 12 weeks and at the endpoint. Par-
ticipants were seen every two weeks and had an emergency 
phone number which they could call 24 h each day. All par-
ticipating clinicians (M.H., C.L., P.R. and S.B.) had at least 
an experience of 6 years in clinical psychiatry.
Outcomes
Primary outcome
The primary outcome was relapse defined as a CGI > 3 AND 
at least two of the following positive PANSS items > 3: delu-
sions, conceptual disorganisation, hallucinations, manner-
isms and posturing and unusual thought content assessed 
at every visit.
Secondary outcomes
The following rating scales were applied:
• “Positive and Negative Syndrome Scale” (PANSS) [22]
• “Subjective well-being under neuroleptics scale (SWN)” 
[23]
• “Personal and Social Performance Scale (PSP)” [24]
• “Medication Adherence Rating Scale (MARS)” [25]
• “Abnormal Involuntary Movement Scale (AIMS)” [26]
All raters were trained in the PANSS by S.H. We assessed 
dropouts due to any reason and due to specific reasons. Side 
effects were measured with the UKU-scale [27]. Olanzapine 
equivalence doses were calculated using the “International 
consensus study of antipsychotic dosing” [28].
Statistical analysis
The intention-to-treat-sample consisted of all participants 
randomized into the trial. The per-protocol-sample were all 
participants completing the trial according to protocol.
The primary dichotomous outcome was the number of 
patients relapsed in the intervention group compared with 
that in the control group. Fisher’s Exact Test was applied to 
compare the number of relapsed patients.
As secondary endpoint time until relapse or study end-
point was graphically presented with Kaplan–Meier curves. 
Group differences in time to relapse were examined with 
the log-rank test. In addition, the median time to relapse for 
both study arms was determined. Cox’s proportional hazard 
model (Cox Regression Analysis) was used to determine the 
effect of treatment parameters age, gender and total PANSS 
score at baseline (independent variable) on the outcome time 
to relapse (dependent variable).
Kolmogorov–Smirnov tests on normality were per-
formed. For continuous outcomes, ANOVA was performed 
to compare data at baseline between the groups, if for a var-
iable there were no significant deviations from normality 
assumption. Mann–Whitney U tests were used, if data were 
tested not to be normally distributed. In case of dichotomous 
variables (e.g. gender), group comparisons were performed 
with Fisher’s Exact Test or with Freeman–Halton test for 
2 × 3 tables.
The changes in the rating scales [overall PANSS score, 
CGI-S, quality of life (SW-N), personal and social func-
tional level (PSP), adherence behavior (MARS), scales for 
the evaluation of movement disorders (AIMS)] from time 
of randomization until the end of study were calculated by 
analysis of covariance (ANCOVA) with treatment (discon-
tinuation or continuation of antipsychotic treatment) as a 
fixed factor and the respective scale value at baseline as a 
covariate. If the assumptions for parametric tests were vio-
lated, Mann–Whitney U test or Freeman-Halton test were 
used as appropriate.
The occurrence of specific side effects (UKU scale) is 
shown descriptively and compared between the groups with 
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Fisher’s Exact Test. Breslow–Day tests were used to analyze, 
if the side effects changed significantly different between the 
groups from baseline until the end of the study. If there were 
missing values at study endpoint, last observation carried 
forward (LOCF) procedure was applied.
The primary statistical analysis followed the intention-to-
treat (ITT) principle defined as all patients being randomized. 
Level of significance was α = 0.05. Therefore the analyses for 
secondary outcomes were explorative. All tests were two-
tailed. SPSS version 25 was used for data analysis.
Role of the funding source
The funder had no role in study design, data collection, 
analysis, or interpretation or writing of the article. The cor-
responding author had access to all study data and had the 
final responsibility for the decision to submit for publication.
Results
Patients
We screened 37 patients between February 1, 2015 and 
December 2015 for study inclusion. Twenty-one of them 
were eligible and gave informed consent. One withdrew con-
sent before randomization and was therefore not available for 
analysis. The initial recruitment aim was 25 patients, but the 
study was prematurely terminated due to lack of resources 
at 20 patients (80% of the planned sample). Eleven patients 
were randomised to the antipsychotic reduction group (inter-
vention) and nine to the maintenance group (control). One 
subject in the intervention group refused to reduce medi-
cation and one in the control group reduced and stopped 
medication. Both were excluded from the per-protocol sam-
ple. The relapsed patient in the control group discontinued 
participation and was lost to follow-up (Fig. 1).
Eleven participants had a diagnosis of paranoid schiz-
ophrenia according to ICD-10 and nine, a diagnosis of 
schizoaffective disorder. The gender distribution was 6 
males/5 females in the intervention group and 6 males/3 
females in the control group. Intervention/control group 
had a mean age of 44.73/46.11 years, a mean duration of 
illness of 16.82/17.89 years, 3.36/4.56 previous episodes 
and no schizophrenic episode for 78.09/96.78 months. The 
antipsychotics in the intervention/control group prescribed 
were aripiprazole (n = 6/n = 1), quetiapine (n = 3/n = 5), 
olanzapine (n = 1/n = 3), risperidone (n = 5/n = 0), and 
perazine (n = 0/n = 1). In the intervention group/control 
group, four patients/one patient took more than one antip-
sychotic and the mean dose in olanzapine equivalents was 
14.4 mg/9.2 mg. There was no significant difference between 
the characteristics of the two groups, except for family his-
tory of psychiatric illness (Table 1).
Primary outcome, Cox‑regression 
and hospitalisation
Two patients in the control group and one in the interven-
tion group fulfilled the relapse criteria (Fisher’s exact test: 
p = 0.566). The patient in the intervention group returned to 
starting dose after relapse, stabilized and did not fulfil the 
relapse criteria anymore. One relapse in the maintenance 
group was associated with social stress (illness of the mother 
of the patient). The patient stabilized over time without any 
change in medication. The other relapsed patient in the con-
trol group stopped medication against protocol, fulfilled 
relapse criteria afterwards, discontinued the study and was 
lost to follow-up. The median time to relapse was 88.5 days 
in the control group and 124 days in the intervention group 
(Log-rank:  chi2 = 0.751, df = 1, p = 0.386) (Supplementary 
Fig. 1).
Using Cox-Regression to explore the influence of age, 
gender or PANSS-Baseline-Score on time to relapse did 
not yield any significant results. There was a trend for the 
moderator age (p = 0.059) (Supplementary Fig. 2), however 
this result was mainly caused by the youngest participant, 
who had the earliest relapse. This was the participant, who 
violated the protocol by reducing medication in the control 
group.
No participant had to be hospitalised during the study. 
Whether the one participant who dropped out was hospi-
talised remained unclear because he was lost to follow-up.
Secondary outcomes
There was no significant difference between groups in terms 
of the mean change from baseline to endpoint of PANSS 
total score and the PANSS subscores. Nor was there a sig-
nificant difference between groups in terms of CGI-improve-
ment, quality of life (SWN-Scale), social functioning (PSP), 
dyskinesia (AIMS), and adherence (MARS) (Table 2).
Safety
There were no serious adverse events or deaths. Side effects 
according to the UKU-scale are presented in Supplementary 
Table 1a + b. There was no significant difference between 
groups for any side effect at baseline or endpoint. In the 
course of the study, the number of patients with orgastic dys-
function decreased in the intervention group but increased 
in the control group (Breslow–Day test: p = 0.013). Dream 
activity increased in the intervention group but decreased in 
the control group (Breslow–Day test: p = 0.011) (details in 
Supplementary Table 1a + b).
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Reduction of doses
The mean reduction of antipsychotic dose in the interven-
tion group, calculated as the arithmetic mean per patient of 
the reduction for each antipsychotic medicament used, was 
42% (range 0–100%) (Table 3), corresponding to a mean 
olanzapine equivalence dose of 9.5 mg/day. In one patient 
medication was stopped completely. Reduction schemes are 
presented in Fig. 2. Doses were not changed in the con-
trol group except for the patient who stopped medication 
himself.
Rescue medication
The participant with the relapse in the intervention 
group took rescue medication (Lorazepam 1 mg) three 
times. Three patients in the control group took rescue 
Fig. 1  Consort-flowchart Screening  (n=37)
Excluded 
(n= 17)









Excluded from analysis: 
(n=0)
Lost to follow-up: 
(n=0)
Discontinuation of treatment: 
(n=0)
Allocated to intervention: 
(„reducing medication“) (n=11)
Treatment as allocated: 
(n=10)
Treatment not as allocated:
(n=1)
Reason: Participant refused 
reduction of medication. 
Lost to follow-up: 
(n=1)
Reason:
Discontinuation of treatment: 
(n=1)
Reason: Participant wish 
Allocated to control 
(„maintenance“):
(n=9)
Treatment as allocated: 
(n=8)
Treatment not as allocated:
(n=1 )
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medication (Lorazepam 1 mg), all due to sleeping prob-
lems and inner tension. The patient who stopped medica-
tion against protocol took rescue medication (Lorazepam 
1 mg) due to craving for alcohol.
The per-protocol analysis did not materially change the 
results.
Power analysis for future studies
From the present study, a power analysis for future studies 
can be derived, intending to show non-inferiority of medi-
cation reduction comparing to a control group maintaining 
at the current dosage, when from the present study relapse 
rates of 15% in both the intervention and the control group 
are estimated. Assuming α = 0.05 and a power of 1 − β = 0.8, 
in both groups 26 patients will be needed to conclude that 
the upper limit of a one-sided 95% confidence interval will 
exclude a superiority in favor of the control group of more 
than 25% [29].
Discussion
To our knowledge, this is the first time guided antipsychotic 
discontinuation was examined in stable chronic schizo-
phrenic patients in a randomized controlled design. The goal 
of this pilot study was to check feasibility and safety. During 
the trial, no patient had to be hospitalized and the single 
patient with a relapse in the intervention was stable at the 
end of the trial after increasing his dose to the original level. 
One participant in the control group, who violated the study 
protocol by abruptly stopping medication, relapsed, dropped 
out and was lost to follow up. The relapse of the other patient 
in the control group was associated with intercurrent illness 
of his mother, showing that even long-term stable medicated 
patients are vulnerable to stress and psychosocial support 
is crucial for a successful reduction of antipsychotic medi-
cation [30]. The mean percentage dose reduction in the 
intervention group was more than 40% in three months, 
which is quite a substantial reduction. As intended the 
sample consisted of patients with chronic schizophrenia 
or schizoaffective disorder with several previous episodes 
and a mean duration of illness of 15 years (Table 1). The 
Table 1  Baseline characteristics 
of the intention to treat sample
Continuous variables were analyzed using ANOVA. Categorical variables were analyzed with Fisher’s 
exact test. a = Mann–Whitney U test, data were not normally distributed. b = Freeman-Halton extension of 
Fisher´s exact test for 2 × 3 field tables. m = mean, sd = standard deviation, F = test statistic, df = degrees of 
freedom, p p value
Characteristic Intervention 
(n = 11)
Control (n = 9) F Statistic
m sd m sd df p
Age (years) 44.73 10.33 46.11 12.09 0.08 1, 18 0.785
Weight (kg) 88.70 10.95 76.88 15.29 3.66 1, 16 0.074
Height (cm) 175.89 5.53 174.13 7.68 0.30 1, 15 0.592
PANSS overall (baseline) 50.09 10.41 47.67 8.09 0.33 1, 18 0.575
PANSS positive-score (baseline) 9.27 2.37 10.11 2.85 0.52 1, 18 0.481
PANSS negative-score (baseline) 13.73 4.47 12.00 4.56 0.73 1, 18 0.405a)
PANSS Allgemein-score (baseline) 27.09 5.74 25.56 5.57 0.36 1, 18 0.554
CGI (Baseline) 2.82 0.41 3.00 0.00 1.80 1, 18 0.196a)
Duration of illness (years) 16.82 8.44 17.89 8.80 0.08 1, 18 0.785
Number of previous hospitalisations 3.00 1.67 3.67 3.28 0.35 1, 18 0.563
Number of previous episodes 3.36 1.75 4.56 2.83 1.34 1, 18 0.263
Duration since last episode (months) 78.09 45.82 96.78 57.28 0.66 1, 18 0.428
Gender (male/female) 6/5 6/3 0.670
Living alone (no/yes) 0/11 1/8 0.450
Married or cohabiting 7/4 3/6 0.370
Educational level (low/middle/high) 3/3/5 2/0/7 0.255b
Continuous occupation (no/yes) 3/8 6/3 0.175




Smoking (no/yes) 5/6 6/3 0.406
Family history of psychiatric disorders (no/yes) 5/6 0/9 0.038
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Table 2  Differences between baseline and endpoint in all secondary outcomes
ANCOVA for all normally distributed outcomes (bold values), Mann–Whitney U test for all others (italic values), except for *Freeman–Halton 
extension of Fisher’s exact test
df degrees of freedom, PANSS positive and negative syndrome scale of schizophrenia, CGI clinical global impression score (V15 vs. V2: 
improved/unchanged/deteriorated). SWN subjective wellbeing under neuroleptics, MARS medication adherence rating scale, PSP personal and 
social performance scale, AIMS abnormal involuntary movement scale, m/median mean for normally distributed and median for non normally 
distributed values, n number of participants, sd standard deviation, LOCF last observation carried forward, V2 visit 2, V15 visit 15
a Negative change scores represent improvement
b Positive change scores represent improvement
Differences V15 − V2 Intervention Control Factor group
n m/median sd/– n m/median sd/– F/U df p
PANSS  totala (LOCF) 11 − 3.45 10.61 9 3.00 9.59 1.55 1, 17 0.230
PANSS positive scorea 
(LOCF)
11 1.0 – 9 0.0 – 45.5 1 0.766
PANSS negative  scorea 
(LOCF)
11 − 3.82 3.52 9 − 0.56 5.29 1.96 1, 17 0.179
PANSS general  scorea 
(LOCF)
11 − 0.55 6.68 9 1.33 2.83 0.16 1, 17 0.691
SWNb (LOCF) 8 1.63 16.34 8 3.88 11.08 0.04 1, 13 0.838
MARS  sumb 11 0.27 1.35 8 0.38 0.92 0.22 1, 16 0.643
PSPb 11 − 10.0 – 8 10.0 – 24.0 1 0.109
AIMSa 11 0.0 – 8 0.0 – 41.5 1 0.840
CGI (LOCF) Improved: n = 3, unchanged: n = 7, deterio-
rated: n = 1
Improved: n = 2, unchanged: n = 6, deterio-
rated: n = 1
– – 1.00*
Table 3  Reduction of 
medication (dosage at study 
end vs. baseline) in patients of 
the intervention group—ITT-
Sample
a Patient refused medication reduction
b Before study start patient had 1 mg oral risperidone daily and 50 mg risperidone depot every 2 weeks. 
Depot medication was switched to 6 mg oral risperidone
c After a relapse the medication had to be raised to the starting dose
d Patient had 400 mg aripiprazole every 4 weeks, which were switched to 20 mg oral aripiprazole daily




Reduction (%) Mean reduction 
per patient (%)
001 Aripiprazole 25 15 40
Quetiapine 150 50 66.7 53.3
002a Risperidone depot 25 25
Quetiapine 50 50 0.0 0
004 Risperidoneb 7 7 0c
Olanzapine 1.25 1.25 0 0
005 Aripiprazoled 20 15 25.0
Quetiapine 50 50 0.0 12.5
007 Risperidone 1 0 100.0 100.0
011 Aripiprazole 30 15 50.0 50.0
014 Aripiprazole 30 20 33.3 33.3
015 Risperidone 3 1 66.7 66.7
016 Aripiprazole 15 7.5 50.0 50.0
018 Risperidone 6 4.5 25.0 25.0
019 Aripiprazole 10 2.5 75.0 75.0
Mean medication reduction in 
the intervention group
42.3
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intention-to-treat population had a higher relapse rate in 
the control group than in the intervention group, but this 
was due to the abrupt withdrawal of a patient in the control 
group. In the per-protocol population one patient per group 
relapsed. None of the outcome measures was significantly 
different between the two groups. Although the sample size 
was small for definitive conclusions, these results make us 
confident that examining gradual and careful dose-reduction 
can be safely assessed in a future randomised trial. The only 
exceptions were increased dream activity and less orgastic 
dysfunction in the intervention group at endpoint.
There are limitations of our study. The sample was small, 
because this was a pilot study with the aim to check the 
feasibility of a larger trial. So all analyses should be seen 
as exploratory. The inclusion of patients with schizoaffec-
tive disorder, could have influenced the results, as there 
are data for a better prognosis for these patients [31]. Of 
the three participants who relapsed two had diagnosis of 
schizoaffective disorder and one a diagnosis of schizophre-
nia. Some participants had additional psychotropic drugs 
like antidepressants or mood stabilizers, which could have 
influenced psychopathology (Supplementary Table 2). But 
these medication had to be stable at least six weeks before 
enrollment and was not changed throughout the study. So 
possible changes in psychopathology cannot be attributed 
to these drugs. Even if clozapine is often used in chronic 
schizophrenic patients, we did not include this drug in our 
study. Our rational was evidence that reduction of clozap-
ine can cause severe rebound psychoses [19]. Two included 
patients violated the protocol. These two patients did not 
reduce or maintain the dose according to the group they 
were allocated. Regardless, excluding them from the analysis 
did not change the results significantly. In time series analy-
sis, the time until the first relapse was analyzed. Whether 
patients remitted again after they had relapsed was not an 
outcome of the study. However, the individual course of 
the patients is described in the section “Primary outcome, 
cox-regression and hospitalization” and indeed all patients 
remitted again. The goal to reduce 1/6 of the antipsychotic 
dose every two weeks was ambitious, but in clinical rou-
tine patients often urge doctors to reduce the dose as fast as 
possible. After all we assume, that a slower dose reduction 
could have prevented or at least delayed the one relapse in 
the reduction group. The follow-up period of three months 
after dose reduction was short and it is possible that more 
relapses occur in the reduction group later on. Furthermore, 
quality of life and social functioning, need time to change, 
eventually up to 7 years as seen in the study by Wunderink 
[32], so possible changes may be missed due to the short 
follow-up period. There is also contrary evidence from a ten 
Fig. 2  Dose reduction from 
baseline to endpoint in original 
doses for the individual subjects
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year naturalistic follow-up of a discontinuation study [33]. In 
the discontinuation group, more patients had a poor clinical 
outcome (39%) than in the maintenance group (21%). Also 
the suicide rate was higher in the discontinuation group (4%) 
than in the maintenance group (2%).
This pilot trial showed that gradual reduction of antip-
sychotic medication in chronic stable schizophrenic 
patients is feasible and can be carefully attempted under 
close supervision, at least in the framework of a rand-
omized trial with study visits every two weeks. Even 
patients that relapsed under dose reduction stabilized after 
raising medication until the end of the trial and no relapsed 
patient had to be hospitalized. As this was a small pilot 
study, results need to be confirmed in a larger trial.
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